Lyon - Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today published its financial agenda for the year 2021.
Publications will take place after the Euronext Paris market close, unless otherwise specified. These dates are given as an indication, they are likely to be modified if necessary.
1st February 2021: Update on cash 31 December 2020
April 7, 2021: 2020 annual financial results and cash flow update as of March 31, 2021
June 16, 2021: Annual General Meeting
July 8, 2021: Cash flow update at June 30, 2021
September 30, 2021: Financial results for the 1st half 2021
October 19, 2021: Cash flow update at September 30, 2021
In addition, Theranexus plans to participate in the following investor events organized in digital version
January 11-14, 2021: JP Morgan Healthcare (digital)
January 26-27, 2021: Biomed Invest Securities Conference (in digital)
February 10, 2021: CF&B Small and Midcap Event, Paris
Founded in 2013, THERANEXUS is a clinical-stage biopharmaceutical company, from the CEA, which develops drug candidates for the treatment of diseases of the nervous system. THERANEXUS has identified the major role of non-neuronal cells (otherwise called 'glial cells') in the response to psychotropic drugs (targeting neurons). The company is a pioneer in the design and development of drug candidates acting on the interaction between neurons and glial cells. The unique and patented technology exploited by THERANEXUS aims to increase the effectiveness of psychotropic drugs already approved and marketed by combining them with a glial cell modulator.
Proprietary and adaptable, the THERANEXUS platform makes it possible to generate various proprietary drug candidates with high added value in several indications.
THERANEXUS is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
Tel: +33 (0) 1 53 67 36 70